Fig. 3

Combination drug screen identifies Navitoclax as a potential sensitizer to GQC-05. The AML cell line KG-1a was treated with a library of 53 cancer drugs or inhibitors at doses ranging from 1 nM – 10 μM and either vehicle (DMSO), 100 nM GQC-05 or 300 nM GQC-05. Cells were assayed for cell number after 72 h of treatment and normalized to untreated cells. Dose response curves were determined for each drug library compound and Area Under the Curve (AUC) was calculated from two biological replicate screens and plotted for (a) DMSO vs 100 nM GQC-05 or (b) DMSO vs 300 nM GQC-05. c AUC values for cells treated with the combination of Navitoclax and either DMSO, 100 nM GQC-05 or 300 nM GQC-05